Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of OT202 Eye Drops in the Treatment of Moderate to Severe Dry Eye

NCT06435182 is registered in ClinicalTrials.gov with Ocumension Therapeutics (Shanghai) Co., Ltd as lead sponsor.

NCT NCT06435182
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06435182 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of OT202 Eye Drops in the Treatment of Moderate to Severe Dry Eye
Lead sponsor
Ocumension Therapeutics (Shanghai) Co., Ltd
Phase
Phase 2
Overall status
Completed
Start date
April 10, 2023
Completion date
January 26, 2024
Enrollment
213 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

dry eye